Screening and early detection of colorectal and lung carcinomas is associated with reduced disease-specific mortality, but screening adherence rates remain suboptimal. Circulating tumor DNA (ctDNA) testing is a sensitive and specific modality validated to detect all-stage colorectal and lung carcinomas in patients eligible for screening. Peripheral blood analysis of ctDNA provides comparable sensitivity and specificity to current standard of care screening regimens for lung and colorectal carcinomas with negligible risk and should be considered in an effort to improve screening adherence rates in the eligible population.
Novruzov L. Circulating Tumor DNA in Screening for Colorectal and Lung Carcinoma. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.